


What is claimed is:

1. A compound of formula (I) :



wherein:

n is 0, 1, or 2;

t is 0 or 1;

X is $-NH-$, $-O-$, $-R^{10}-$, $-OR^{10}-$, $-R^{10}O-$, $-R^{10}OR^{10}-$, $-NR^{10}-$, $-R^{10}N-$, $-R^{10}NR^{10}-$, $-R^{10}S(O)_m-$, or $-R^{10}S(O)_mR^{10}-$;

Y is $-C(O)-$ or $-S(O)_m-$;

each R is the same or different and is independently selected from the group consisting of

halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-R^{10}$ cycloalkyl, Ay, $-NHR^{10}$ Ay, Het, $-NHHet$, $-NHR^{10}Het$, $-OR^2$, $-OAY$, $-OHet$, $-R^{10}OR^2$, $-NR^2R^3$, $-NR^2Ay$, $-R^{10}NR^2R^3$, $-R^{10}NR^2Ay$, $-R^{10}C(O)R^2$, $-C(O)R^2$, $-CO_2R^2$, $-R^{10}CO_2R^2$, $-C(O)NR^2R^3$, $-C(O)Ay$, $-C(O)NR^2Ay$, $-C(O)Het$, $-C(O)NHR^{10}Het$, $-R^{10}C(O)NR^2R^3$, $-C(S)NR^2R^3$, $-R^{10}C(S)NR^2R^3$, $-R^{10}NHC(NH)NR^2R^3$, $-C(NH)NR^2R^3$, $-R^{10}C(NH)NR^2R^3$, $-S(O)_2NR^2R^3$, $-S(O)_2NR^2Ay$, $-R^{10}SO_2NHCOR^2$, $-R^{10}SO_2NR^2R^3$, $-R^{10}SO_2R^2$, $-S(O)_mR^2$, $-S(O)_mAy$, cyano, nitro, or azido;

each R^1 is the same or different and is independently selected from the group

consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-R^{10}$ cycloalkyl, Ay, $-NHR^{10}$ Ay, Het, $-NHHet$, $-NHR^{10}Het$, $-OR^2$, $-OAY$, $-OHet$, $-R^{10}OR^2$, $-NR^2R^3$, $-NR^2Ay$, $-R^{10}NR^2R^3$, $-R^{10}NR^2Ay$, $-R^{10}C(O)R^2$, $-C(O)R^2$, $-CO_2R^2$, $-R^{10}CO_2R^2$, $-C(O)NR^2R^3$, $-C(O)Ay$, $-C(O)NR^2Ay$, $-C(O)Het$, $-C(O)NHR^{10}Het$, $-R^{10}C(O)NR^2R^3$, $-C(S)NR^2R^3$, $-R^{10}C(S)NR^2R^3$, $-R^{10}NHC(NH)NR^2R^3$, $-C(NH)NR^2R^3$, $-R^{10}C(NH)NR^2R^3$, $-S(O)_2NR^2R^3$, $-S(O)_2NR^2Ay$, $-R^{10}SO_2NHCOR^2$, $-R^{10}SO_2NR^2R^3$, $-R^{10}SO_2R^2$, $-S(O)_mR^2$, $-S(O)_mAy$, cyano, nitro, or azido;

each m independently is 0, 1, or 2;

each R^{10} is the same or different and is independently selected from alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene;

p and q are each independently selected from 0, 1, 2, 3, 4, or 5;

each of R^2 and R^3 are the same or different and are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-R^{10}$ cycloalkyl, $-R^{10}OH$, $-R^{10}(OR^{10})_w$, and $-R^{10}NR^4R^5$;

w is 1-10;

each of R^4 and R^5 are the same or different and are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;

Ay represents an aryl group;


Het represents a 5- or 6-membered heterocyclyl or heteroaryl group;


ring A is aryl or heteroaryl;

provided that when the A ring is aryl, t is 0, and Y is SO_2 , then p is not 0; and salts, solvates and physiologically functional derivatives thereof.

2. The compound of claim 1 wherein alkyl is C_1 - C_6 alkyl, alkoxy is C_1 - C_6 alkoxy, haloalkyl is C_1 - C_6 haloalkyl, alkylene is C_1 - C_6 alkylene, and alkenylene is C_1 - C_6 alkenylene.
3. The compound wherein t is 0 and Y is $-C(O)-$.
4. The compound wherein t is 0 and Y is $-S(O)_m-$.
5. The compound of claim 1 wherein t is 1, Y is $-C(O)-$, and X is $-NH-$, $-O-$, $-R^{10}-$, or $-OR^{10}-$.
6. The compound of claim 1 wherein t is 1, Y is $-S(O)_m-$, and X is $-NH-$, $-O-$, $-R^{10}-$, or $-OR^{10}-$.
7. The compound of claim 1 wherein n is 1.
8. The compound of claim 1 wherein p is 1 or more and R is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, cyano, nitro, or azido.
9. The compound of claim 8 wherein R is halogen, alkyl, haloalkyl.
10. The compound of claim 9 wherein R is substituted *para* to the depicted N atom.
11. The compound of claim 10 wherein R is halogen.
12. The compound of claim 11 wherein R is Br or Cl.
13. The compound of claim 1 wherein q is 1 or more and R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, Ay, Het, cyano, nitro, or azido.
14. The compound of claim 13 wherein R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, or cyano.

15. The compound of claim 14 wherein R^2 and R^3 each are C_1 - C_6 alkyl.
16. The compound of claim 14 wherein R^1 is selected from halogen, alkyl, or $-OR^2$.
17. The compound of claim 16 wherein said halogen is fluoro or chloro, said alkyl is methyl, and said $-OR^2$ is alkoxy.
18. The compound of claim 1 wherein the A ring is aryl.
19. The compound of claim 18 wherein the A ring is phenyl.
20. The compound of claim 19 wherein q is 1 or more and R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, Ay, Het, cyano, nitro, or azido.
21. The compound of claim 20 wherein q is 1 or more and R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, or cyano.
22. The compound of claim 1 wherein the A ring is heteroaryl.
23. The compound of claim 22 wherein the heteroaryl is pyridyl.
24. The compound of claim 23 wherein q is 0 or 1.
25. The compound of claim 24 wherein when q is 1, then R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, Ay, Het, cyano, nitro, or azido.
26. The compound of claim 25 wherein when q is 1, then R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, or cyano.
27. The compound of claim 1 wherein p is 1, R is halogen, n is 1, Y is $-C(O)-$, t is 0, ring A is heteroaryl, and q is 0.
28. The compound of claim 27 wherein R is chloro and ring A is pyridyl.
29. A compound selected from:





30. The compound of claim 1 selected from
- N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-phenylurea;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-(4-methoxyphenyl)urea;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-(4-methoxy-2-methylphenyl)urea;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-(3-chloro-4-methoxyphenyl)urea;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-[4-(dimethylamino)phenyl]urea;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
 - N*-[(1*R*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
 - N*-[(1*S*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-phenylacetamide;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-phenylpropanamide;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-phenylprop-2-enamide;
 - Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-dichlorobenzamide;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-fluorobenzamide;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-chlorobenzamide;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide;
 - N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-(trifluoromethyl)benzamide;

N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-nitrobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-chlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-methylbenzamide;
N-(2,3,4,9-Tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)pyridine-2-carboxamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)nicotinamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-6-chloronicotinamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)isonicotinamide;
N-Phenyl-*N'*-(2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)urea;
N-(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-phenylurea;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-phenylurea;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;
N-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;
N-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-imidazole-5-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-pyrazole-5-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-pyrazole-3-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-imidazole-4-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-pyrazole-3-carboxamide;

N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide;
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide; and
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzenesulfonamide.


31. The compound of claim 1 selected from
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-[4-(dimethylamino)phenyl]urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-phenylprop-2-enamide;
Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-chlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-(trifluoromethyl)benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-methylbenzamide;
N-(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)pyridine-2-carboxamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)nicotinamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-6-chloronicotinamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)isonicotinamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-imidazole-4-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-pyrazole-3-carboxamide;

N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide;
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide; and
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzenesulfonamide.

32. The compound of claim 1 selected from

N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
 Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-chlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-(6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)pyridine-2-carboxamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-6-chloronicotinamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide; and
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide.

33. The compound of claim 1 further comprising:



Including salts, solvates and pharmaceutically functional derivatives, wherein R^6 is H, alkyl, $-OR^2$, $-NR^2R^3$, Ay, Het, $-C(O)R^2$, $-CO_2R^2$, $-CONR^2R^3$, $-S(O)_mR^2$, or oxo, where R^2 , R^3 , m, Ay, and Het are as defined; and R^7 is H or alkyl; provided R^6 and R^7 are not both H.

34. The compound of claims 1 to 33 substantially as hereinbefore defined with reference to any one of the Examples.
35. A pharmaceutical composition comprising a compound according to claims 1 to 33, and a pharmaceutically acceptable carrier.
36. A compound according to claims 1 to 33 for use as an active therapeutic substance.
37. A compound according to claims 1 to 33 for use in the treatment or prophylaxis of diseases and conditions caused by oncogenic viruses, including adenoviruses, retroviruses, and papovavirus family, including polyoma viruses and papilloma viruses.
38. A compound according to claims 1 to 33 for use in the treatment or prophylaxis of conditions or disorders due to HPV infection.
39. The compound of claim 38 wherein the condition or disease is warts, genital warts, cervical dysplasia, recurrent respiratory papillomatosis, or cancers associated with papillomavirus infection.
40. The compound of claim 39 wherein the cancer is anogenital cancers, head and neck cancers, and skin cancers.
41. The compound of claim 40 wherein
the anogenital cancers are cervical, anal and perianal, vulvar, vaginal, and penile cancers;
the head and neck cancers are oral pharyngeal region and esophagus cancers; and
the skin cancers are basal cell carcinoma and squamous cell carcinoma.
42. Use of a compound according to any one of claims 1 to 33 in the manufacture of a medicament for use in the treatment or prophylaxis of oncogenic viruses, including adenoviruses, retroviruses, and papovavirus family, including polyoma viruses and papilloma viruses.
43. Use of a compound according to claims 1 to 33 in the manufacture of a medicament for use in the treatment or prophylaxis of conditions or disorders due to HPV infection.

44. Use of a compound as in claim 43 wherein the condition or disorder is warts, genital warts, cervical dysplasia, recurrent respiratory papillomatosis, or cancers associated with papillomavirus infection.
45. A method for the treatment or prophylaxis of oncogenic viruses, including adenoviruses, retroviruses, and papovavirus family, including polyoma viruses and papilloma viruses comprising the administration of a compound according to any one of claims 1 to 33.
46. A method for the treatment or prophylaxis of conditions or disorders due to HPV infection comprising the administration of a compound according to any one of claims 1 to 33.
47. The method of claim 46 wherein the condition or disorder is warts, genital warts, cervical dysplasia, recurrent respiratory papillomatosis, or cancers associated with papillomavirus infection.